http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105412089-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 |
| filingDate | 2015-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105412089-B |
| titleOfInvention | Applications of the compound VS1 in anti-non-small cell lung cancer drug is prepared |
| abstract | The present invention relates to the new opplications of known compound, and in particular to applications of the compound VS1 in anti-non-small cell lung cancer drug is prepared.Empirical tests above-claimed cpd has obvious inhibiting effect to Lines, available for preparing anti-non-small cell lung cancer drug.The present invention obtains the compound for having obvious inhibiting effect to Lines by screening using ERBB3 as action target, it is intended to provide the lead compound of candidate for the new drug development of anti-non-small cell lung cancer drug. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4029500-A1 |
| priorityDate | 2015-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.